Sign up for news & promotions:
MSLN Primary Antibody
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|IHC_P (Immunohistochemistry)||Purified recombinant fragment of human MSLN (AA: 37-286) expressed in E. Coli.|
|FCM (Flow Cytometry)||1/200 - 1/400|
|(AA: 37-286) expressed in E. Coli.|
Figure 1: Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Figure 2: Western blot analysis using MSLN mAb against human MSLN (AA: 37-286) recombinant protein. (Expected MW is 52.7 kDa)
Figure 3: Western blot analysis using MSLN mAb against HEK293 (1) and MSLN (AA: 37-286)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4: Flow cytometric analysis of Hela cells using MSLN mouse mAb (green) and negative control (red).
|Tissue Array Results|
|View Full Documents|
This gene encodes a preproprotein that is proteolytically processed to generate two protein products, megakaryocyte potentiating factor and mesothelin. Megakaryocyte potentiating factor functions as a cytokine that can stimulate colony formation of bone marrow megakaryocytes. Mesothelin is a glycosylphosphatidylinositol-anchored cell-surface protein that may function as a cell adhesion protein. This protein is overexpressed in epithelial mesotheliomas, ovarian cancers and in specific squamous cell carcinomas. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.
|References (references)||1.Tumour Biol. 2018 Oct;40(10):1010428318804937.
2.Mol Cancer. 2017 Mar 14;16(1):63.